



ALKEM LABORATORIES LTD.

Regd. Office : " ALKEM HOUSE", Senapati Bapat Marg,
Lower Parel, MUMBAI 400 013. Phone : 3982 9999, Fax : 022-2495 2955
Email : contact@alkem.com Website : www.alkemlabs.com
CIN no :- U00305MH1973PLC174201



7th June, 2016

| | |
|---|---|
| The Corporate Relationship Department BSE Limited Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai 400 001. <i>Scrip Code: 539523</i> | National Stock Exchange of India Limited Exchange Plaza, Bandra Kurla Complex, Bandra East , Mumbai 400 051. <i>Scrip Symbol: ALKEM</i> |
|---|---|

Dear Sirs

Sub: Closure of UK MHRA Inspection – Company’s Bioequivalence facility at Taloja stands UK-MHRA compliant.

In furtherance to the intimation captioned “UK MHRA Inspection Update” dated 31st March, 2016, this is to inform you that the GCP Inspectorate has reviewed the corrective and preventive actions submitted by the Company and has considered them acceptable. Accordingly, Company’s Bioequivalence Facility at Taloja stands UK-MHRA compliant.

A copy of Press Release is enclosed herewith for your information. Kindly take the same on record.

Sincerely,
For Alkem Laboratories Limited

Manish Narang
Sr. V.P. Legal, Company Secretary & Compliance Officer



ALKEM

ALKEM LABORATORIES LTD.

Regd. Office : " ALKEM HOUSE", Senapati Bapat Marg,
Lower Parel, MUMBAI 400 013. Phone : 3982 9999, Fax : 022-2495 2955
Email : contact@alkem.com Website : www.alkemlabs.com
CIN no :- U00305MH1973PLC174201



Alkem announces closure of UK-MHRA inspection for its Bioequivalence Facility at Taloja

Mumbai, June 7, 2016: Alkem Labs Ltd (Alkem) announced today the closure of the inspection by the United Kingdom – The Medicines and Healthcare Products Regulatory Agency (“UK-MHRA”) for its Bioequivalence Facility at Taloja. The facility stands UK-MHRA compliant.

The UK-MHRA had inspected the Bioequivalence Facility at Taloja from 14th to 18th March 2016 and had notified its observations in a report dated 30th March, 2016. The GCP Inspectorate has reviewed the corrective and preventive actions submitted by the company and has considered them acceptable.

About Alkem Laboratories Ltd.

Established in 1973 and headquartered in Mumbai, Alkem (NSE: ALKEM, BSE: 539523, Bloomberg: ALKEM.IN, Reuters: ALKE.NS) is a leading Indian pharmaceutical company with global operations, engaged in the development, manufacture and sale of pharmaceutical and nutraceutical products. The Company produces branded generics, generic drugs, active pharmaceutical ingredients (APIs) and nutraceuticals, which it markets in India and International markets. With a portfolio of more than 700 brands in India, Alkem is ranked the fifth largest pharmaceutical company in India in terms of domestic sales (Source: IMS SSA MAT March 2016). The Company also has presence in more than 50 international markets, with the United States being its key focus market.

For more information on Alkem Laboratories Ltd., please visit www.alkemlabs.com

For further information or queries please contact

Gagan Borana

Investor Relations – Alkem Laboratories Ltd.

Tel: +91 22 3982 9960 / Mobile: +91 98190 56333

E-mail: gagan.borana@alkem.com